找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Nanoformulations in Human Health; Challenges and Appro Sushama Talegaonkar,Mahendra Rai Book 2020 Springer Nature Switzerland AG 2020 nanot

[復(fù)制鏈接]
樓主: 鳥場
51#
發(fā)表于 2025-3-30 11:47:45 | 只看該作者
Preformulation Challenges: The Concept Behind the Selection, Design and Preparation of Nanoformulati; strategy to improve the low entrapment efficiency and stability, etc. This chapter comprehensively summarizes all these aspects of nanoformulation development and proposes solutions for these challenges. Although a variety of nanoformulations have been described in literature, this chapter is rest
52#
發(fā)表于 2025-3-30 14:46:06 | 只看該作者
53#
發(fā)表于 2025-3-30 19:17:28 | 只看該作者
54#
發(fā)表于 2025-3-30 23:48:23 | 只看該作者
Recent Developments and Challenges in Nanoformulations Targeting Various Ailments of the Colontructure remains integrated due to minimum enzymatic activity..In recent years, the advancement in nanotechnology has tremendously helped target drugs to the colon. The nanoformulations target the drugs to the colon by using simple approaches that may be based on size, pH sensitivity, surface charge
55#
發(fā)表于 2025-3-31 03:53:42 | 只看該作者
56#
發(fā)表于 2025-3-31 07:07:15 | 只看該作者
57#
發(fā)表于 2025-3-31 11:24:35 | 只看該作者
Application of Biocompatible Nanocarriers in Glaucoma: Challenges and Advancesile, dosing frequency, systemic untoward effect, and poor patient compliance. Low drug bioavailability due to transient contact time, rapid washout by tearing, nasolacrimal drainage are some of the major issues related to the ocular pharmacotherapy. To overcome these challenges, novel biocompatible
58#
發(fā)表于 2025-3-31 14:53:01 | 只看該作者
59#
發(fā)表于 2025-3-31 18:14:40 | 只看該作者
60#
發(fā)表于 2025-3-31 23:55:28 | 只看該作者
Nanosized Labile and Particulate Ingredients in Topical Formulations: A Strategic Approach Against Pf the major cosmetic concerns and designing a broad spectrum photoprotective formulation is the need of the hour. Drugs generally used in treating skin ailments fall in the category of anti-allergic and anti-inflammatory agents, antioxidants, anti-infectives, immunosuppressants and anticancer agents
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-6 03:32
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
浦城县| 萝北县| 中西区| 融水| 利辛县| 高平市| 刚察县| 舒兰市| 临泉县| 应城市| 乐山市| 奇台县| 三原县| 板桥市| 改则县| 本溪| 子长县| 仁寿县| 丹东市| 孟村| 长沙县| 淮南市| 美姑县| 商都县| 石渠县| 梨树县| 阳谷县| 怀仁县| 万盛区| 清徐县| 宜丰县| 栾城县| 长泰县| 虞城县| 峨边| 云林县| 阜城县| 临江市| 常州市| 井冈山市| 郧西县|